Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox extension study in β-thalassemia and rare chronic anemia
NCT00303329Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2004
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in hemosiderosis, sponsored by Novartis. Primary endpoint: Adverse Events at 60 months. Started Mar 2004; status: completed.
02
Drugs
deferasirox
03
Conditions
hemosiderosis
Beyond the preview
Go deeper on NCT00303329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303329.